Slide 1: Q2/2026 & H1/2026 Investors Call
August 2026 Q2/2026 & H1/2026 Investors Call NASDAQ: KMDA; TASE: KMDA.TA
Slide 2: Forward-Looking Statement
2 FORWARD- LOOKING STATEMENT This presentation is not intended to provide investment or medical advice. This presentation contains forward-looking statements, which express the current beliefs and expectations of Kamada's management. Such statements include the 2026 financial guidance; roadmap for c
Slide 3: Record-High Quarter & First Half Financial Results
3 RECORD-HIGH QUARTER & FIRST HALF FINANCIAL RESULTS; STRONGEST IN KAMADA'S HISTORY CONTINUE TO EXECUTE ON OUR PLAN; DELIVERING ANOTHER YEAR OF DOUBLE- DIGIT PROFITABLE GROWTH
Slide 4: H1 Delivering Record-High Results YoY Double Digit Revenue and Profitable Increase
4 H 1 - 26 DELIVERING RECORD - HIGH RESULTS YoY DOUBLE DIGIT REVENUE AND PROFITABLE INCREASE Adj. EBITDA REVENUE 14% 2025 $22.5 2026 $ 25.7 13% 2025 $88.8 2026 $ 100.2 Operating Cash Flow EPS 137% 2025 $7.5 2026 $ 17.8 21% 2025 $0.19 2026 $0.23 Paid special cash dividend of $0.25 per share (totaling
Slide 5: Delivering Annual Double-Digit Profitable Growth
5 DELIVERING ANNUAL DOUBLE-DIGIT PROFITABLE GROWTH 6 6% 18 14% 24 17% 34 21% 42 23% 50-53 ~25% 2021 2022 2023 2024 2025 2026 104 129 142 161 180 200- 205 2021 2022 2023 2024 2025 2026 ADJUSTED EBITDA US$M 53% CAGR 2026 represents annual guidance; H1/26 actual performance 2026 represents annual guida
Slide 6: Kamada's Growth Drivers
6 KAMADA'S GROWTH DRIVERS Specialty Plasma Therapies Portfolio of 6 FDA-approved products marketed in over 30 territories In-licensing Partnerships Commercialization & Distribution of third parties' biopharmaceutical products in Israel & MENA Plasma Sales Secured a 3-year $50M plasma sales agreement
Slide 7: FDA-Approved Specialty Plasma Products
7 6 FDA-APPROVED SPECIALTY PLASMA PRODUCTS KEY FOCUS ON TRANSPLANTS & RARE CONDITIONS For Important Safety Information, visit www.Kamada.com KEDRAB® [Rabies Immune Globulin (Human)] Post exposure prophylaxis of rabies infection GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] Augmentation therapy for
Slide 8: Distribution Segment Growth
8 DISTRIBUTION SEGMENT GROWTH More than 25 products exclusively licensed from leading international pharmaceutical companies, marketed in the Israeli market EXCLUSIVE DISTRIBUTOR IN ISRAEL & MENA FOR BIOPHARMACEUTICAL COMPANIES Key areas: plasma-derived, respiratory, rare diseases, infectious diseas
Slide 9: Kamada Plasma: Expanding Vertical Integration & Revenue Growth
9 KAMADA PLASMA EXPANDING VERTICAL INTEGRATION & REVENUE GROWTH Collecting hyper-immune plasma for our specialty IgG products and normal source plasma (NSP) to support revenue growth Operating three FDA Approved plasma collection centers in Texas; Houston, San Antonio and Beaumont In July 2026 annou
Slide 10: M&A Transactions
10 M&A TRANSACTIONS AIMING TO SECURE NEW BUSINESS DEVELOPMENT AND M&A TRANSACTIONS LEVERAGING OVERALL FINANCIAL STRENGTH AND COMMERCIAL INFRASTRUCTURE Screening strategic business development opportunities to identify potential acquisition or in-licensing to accelerate long-term growth Focusing on p
Slide 11: Record-High H1-26 Financial Results
11 1. AdjustedEBITDA is definedas net income,plus (i) tax expense,(ii) financialincome (expense),net, (iii) depreciation and amortization; and (iv) non-cash share-basedcompensation expenses RECORD-HIGH H1-26 FINANCIAL RESULTS US $ M H1/26 H1/25 Q2/26 Q2/25 FY/2025 DETAILS PROPRIETARY 83.9 78.5 47.7
Slide 12: Delivering Annual Double-Digit Profitable Growth
12 DELIVERING ANNUAL DOUBLE-DIGIT PROFITABLE GROWTH 6 6% 18 14% 24 17% 34 21% 42 23% 50-53 ~25% 2021 2022 2023 2024 2025 2026 104 129 142 161 180 200- 205 2021 2022 2023 2024 2025 2026 ADJUSTED EBITDA US$M 53% CAGR 2026 represents annual guidance; H1/26 actual performance 2026 represents annual guid
Slide 13: Thank You
THANK YOU www.kamada.com NASDAQ: KMDA; TASE: KMDA.TA
Slide 14: Kamada - A Global Biopharmaceutical Company
KEDRAB® CYTOGAM® HEPAGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA - A GLOBAL BIOPHARMACEUTICAL COMPANY 6 FDA- Approved Products 14% CAGR (from 2021) $200-205M1 2026 Revenues Guidance $50-53M1 2026 Adj. EBIDTA Guidance 4 Growth Drivers A LEADER IN SPECIALTY PLASMA THERAPIES, WITH A PORTFOLIO OF MARKETED P
Slide 15: Non-IFRS Measures – Adjusted EBITDA
15 NON-IFRS MEASURES – ADJUSTED EBITDA AdjustedEBITDA is definedas net income,plus (i) tax expense,(ii) financialincome (expense),net, (iii) depreciation and amortization; and (iv) non-cash share-basedcompensation expenses US $ M H1/26 H1/25 Q2/26 Q2/25 FY/2025 NET PROFIT 13.4 11.3 9.3 7.4 20.2 TAXE
Slide 16: A Global Leader in Anti-Rabies Immune Globulin (HRIG)
$180M Total estimated U.S HRIG market size The only anti-Rabies IgG product with FDA approved label confirming safety and effectiveness in children KEDRAB/KAMRAB $54M (2025 revenues) 2026 demand demonstrating continues growth year over year Only 2 FDA approved products Leading HRIG in Canada, Austra
Slide 17: GLASSIA
17 Licensed to Takeda in the USA, Canada, Australia and New Zealand Commencing in 2022 , Takeda is paying Kamada royalties, at a rate of 6 % through 2040 ; Projected royalties in the range of $ 10 M to $ 20 M per year Outside the Takeda territories, GLASSIA is marketed by Kamada through a network of
Slide 18: CYTOGAM
18 CYTOGAM $17M 2025 Revenues CMV IMMUNE GLOBULIN Sales Growth To be supported by new clinical data demonstrating product's unique properties CYTOGAM is the only plasma-derived IgG approved in the U.S. and Canada for prophylaxis of CMV disease after Solid Organ Transplantation. CMV is the leading ca